X P Ioannou, P Griebel, A Mena, S M Gomis, D L Godson, G Mutwiri, R Hecker, L A Babiuk, S van Drunen Littel-van den Hurk
{"title":"CpG低聚脱氧核苷酸在兽药中的安全性。","authors":"X P Ioannou, P Griebel, A Mena, S M Gomis, D L Godson, G Mutwiri, R Hecker, L A Babiuk, S van Drunen Littel-van den Hurk","doi":"10.1089/108729003768247628","DOIUrl":null,"url":null,"abstract":"Bacterial DNA and synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs in particular sequence contexts (CpG ODN) are recognized as a danger signal by the innate immune system of vertebrates. For this reason, CpG ODNs have a potential application as both an adjuvant and nonspecific immune modulator and are currently being evaluated in a number of human and veterinary clinical trials. Given their potent immunostimulatory activity, CpG ODNs could possibly induce adverse reactions. As all adjuvants and immune modulators must be nontoxic to meet safety requirements, it was essential to address the safety aspects of CpG ODNs. The current review summarizes experiments carried out to date to establish the safety of CpG ODNs in animals.","PeriodicalId":7996,"journal":{"name":"Antisense & nucleic acid drug development","volume":"13 3","pages":"157-67"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/108729003768247628","citationCount":"23","resultStr":"{\"title\":\"Safety of CpG oligodeoxynucleotides in veterinary species.\",\"authors\":\"X P Ioannou, P Griebel, A Mena, S M Gomis, D L Godson, G Mutwiri, R Hecker, L A Babiuk, S van Drunen Littel-van den Hurk\",\"doi\":\"10.1089/108729003768247628\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bacterial DNA and synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs in particular sequence contexts (CpG ODN) are recognized as a danger signal by the innate immune system of vertebrates. For this reason, CpG ODNs have a potential application as both an adjuvant and nonspecific immune modulator and are currently being evaluated in a number of human and veterinary clinical trials. Given their potent immunostimulatory activity, CpG ODNs could possibly induce adverse reactions. As all adjuvants and immune modulators must be nontoxic to meet safety requirements, it was essential to address the safety aspects of CpG ODNs. The current review summarizes experiments carried out to date to establish the safety of CpG ODNs in animals.\",\"PeriodicalId\":7996,\"journal\":{\"name\":\"Antisense & nucleic acid drug development\",\"volume\":\"13 3\",\"pages\":\"157-67\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1089/108729003768247628\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antisense & nucleic acid drug development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/108729003768247628\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antisense & nucleic acid drug development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/108729003768247628","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Safety of CpG oligodeoxynucleotides in veterinary species.
Bacterial DNA and synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs in particular sequence contexts (CpG ODN) are recognized as a danger signal by the innate immune system of vertebrates. For this reason, CpG ODNs have a potential application as both an adjuvant and nonspecific immune modulator and are currently being evaluated in a number of human and veterinary clinical trials. Given their potent immunostimulatory activity, CpG ODNs could possibly induce adverse reactions. As all adjuvants and immune modulators must be nontoxic to meet safety requirements, it was essential to address the safety aspects of CpG ODNs. The current review summarizes experiments carried out to date to establish the safety of CpG ODNs in animals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
